Latest filing published 06 Oct 2026 for Artiva Biotherapeutics, Inc., €219k.
Insider track record
No signal scores available.
Fred Aslan: trading record in brief
Fred Aslan discloses dealings in Artiva Biotherapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 8 September 2026 to 6 October 2026, the count stands at 2 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 6 October 2026, the filings show a transaction worth €219k in Artiva Biotherapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Fred Aslan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 34,465 shares@ US$7.13CommonSEC144:0001950047-26-010072
- 23,429 shares@ US$11.190.070% mcap100.0% of flowCommonSEC144:0001950047-26-009217
2 of 2 declarations